Logo

KTTA

Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp. • NASDAQ
$1.47 ▲ 38.68% (+0.41)
Market Cap $10.94 M
52w High $3.85
52w Low $0.28
Dividend Yield 0%
P/E -0.33
Volume 85.95M
Outstanding Shares 7.44M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.929M ▼ $-3.037M ▲ 0% $-0.41 ▲ $-2.856M ▲
Q2-2025 $0 $3.811M ▲ $-3.716M ▼ 0% $-0.66 ▲ $-3.649M ▼
Q1-2025 $0 $3.68M ▲ $-3.563M ▼ 0% $-3.25 ▼ $-3.518M ▼
Q4-2024 $0 $3.097M ▲ $-3.178M ▼ 0% $-2.9 ▼ $-3.015M ▼
Q3-2024 $0 $3.005M $-3M 0% $-2.87 $-2.842M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.123M ▼ $13.631M ▼ $1.424M ▼ $12.207M ▼
Q2-2025 $7.217M ▲ $17.009M ▲ $1.831M ▲ $15.178M ▲
Q1-2025 $5.341M ▼ $14.659M ▼ $1.68M ▲ $12.979M ▼
Q4-2024 $6.923M ▼ $16.065M ▼ $1.282M ▲ $14.783M ▼
Q3-2024 $9.361M $18.637M $823.975K $17.813M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.037M ▲ $-2.89M ▲ $0 $-116.145K ▼ $-2.994M ▼ $-2.89M ▲
Q2-2025 $-3.716M ▼ $-3.869M ▼ $0 $5.739M ▲ $1.876M ▲ $-3.869M ▼
Q1-2025 $-3.563M ▼ $-3.056M ▼ $0 $1.474M ▲ $-1.581M ▲ $-3.056M ▼
Q4-2024 $-3.178M ▼ $-2.443M ▲ $0 $-23.55K ▼ $-2.438M ▼ $-2.443M ▲
Q3-2024 $-3M $-3.12M $0 $4.541M $1.394M $-3.12M

Five-Year Company Overview

Income Statement

Income Statement Pasithea is still a pure research-stage biotech with no product revenue so far. Its income statement is dominated by research and corporate costs, which lead to ongoing net losses each year. The per‑share loss looks large mainly because of the reverse stock split, not because the business suddenly worsened. Overall, this is a typical early‑stage biotech profile: expenses tied to R&D and operations, no commercial income yet, and a clear reliance on external funding rather than internally generated profits.

Balance Sheet

Balance Sheet The balance sheet is small but simple. The company holds a modest amount of cash and very few other assets, with no financial debt reported, which reduces balance‑sheet risk. Equity has been shrinking over time as losses accumulate, but it remains positive. The key point is that the asset base is light, cash is the main resource, and the company’s future flexibility will depend on its ability to refill that cash through new funding as development progresses.

Cash Flow

Cash Flow Cash flow reflects a company that is spending to develop drugs, not one that is generating cash. Operating cash flow is negative, and free cash flow is effectively the same, because there is little to no spending on physical assets. This means most cash usage is going directly into R&D and operating costs. Sustainability of this burn will depend on continued access to capital markets, partnership funding, or grants, which is a central uncertainty for a small biotech at this stage.

Competitive Edge

Competitive Edge Pasithea is a very small player in a highly competitive field, going up against larger biotech and pharma companies in cancer and central nervous system disorders. Its competitive angle centers on a potentially safer, more convenient macrocyclic MEK inhibitor and a focus on diseases with significant unmet need, such as NF1 and ALS. Strong patent coverage around PAS‑004 is a plus, but the company is highly dependent on this lead program, and its position will ultimately be determined by how clinical data stack up against existing and emerging treatments.

Innovation and R&D

Innovation and R&D Innovation is the core of Pasithea’s story. The lead candidate, PAS‑004, is designed to improve on older MEK inhibitors by offering better safety and dosing convenience, with early data suggesting a promising profile. Beyond this, the pipeline includes a monoclonal antibody program (PAS‑003) for neuroinflammatory diseases and an early‑stage small molecule program, plus a distinctive collaboration in virtual and augmented reality tools for psychiatric care. All of this signals a strong R&D and innovation focus, but success will hinge on translating these scientific ideas into clear, positive clinical trial results.

Summary

Pasithea is a young, clinical‑stage biotech: no revenue, ongoing losses, modest cash, and no debt, with value tied almost entirely to the success of its research programs. The company’s main attraction is its differentiated macrocyclic MEK inhibitor and a pipeline aimed at serious, underserved diseases, backed by patents and some non‑dilutive support such as an ALS grant. On the other hand, it faces the usual early‑stage biotech risks: heavy dependence on a few key assets, the high failure rate of clinical trials, and the need to keep raising capital to fund operations. Investors typically watch upcoming clinical readouts, cash runway, and partnering activity as the main drivers of how the story could evolve from here.

NEWS

November 28, 2025 · 9:20 AM UTC

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Read more

November 24, 2025 · 7:00 AM UTC

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Read more

November 21, 2025 · 12:35 PM UTC

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Read more

November 20, 2025 · 4:01 PM UTC

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Read more

November 4, 2025 · 7:03 AM UTC

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Read more